A New Peptide Vaccine OCV-501: In Vitro Pharmacology and Phase 1 Study in Patients With Acute Myeloid Leukemia

Cancer Immunology, Immunotherapy - Germany
doi 10.1007/s00262-017-1981-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phase 1 Study of the MDM2 Antagonist RO6839921 in Patients With Acute Myeloid Leukemia

Investigational New Drugs
OncologyPharmacology
2020English

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

The mTOR Inhibitor Everolimus in Combination With Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Phase Ib/Ii Study

Oncotarget
Oncology
2016English

Challenges in Treating Older Patients With Acute Myeloid Leukemia

Journal of Oncology
Oncology
2010English

New Treatments and Strategies in Acute Myeloid Leukemia

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2011English

A Phase I Study of Selinexor in Combination With High-Dose Cytarabine and Mitoxantrone for Remission Induction in Patients With Acute Myeloid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2018English

A Phase II Study of Bortezomib in Combination With Pegylated Liposomal Doxorubicin for Acute Myeloid Leukemia

American Journal of Hematology
Hematology
2019English

New Molecular Markers in Acute Myeloid Leukemia

2011English

AML1 (Acute Myeloid Leukemia 1)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy